Andrew Davis - Feb 27, 2023 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Feb 27, 2023
Transactions value $
-$40,586
Form type
4
Date filed
3/1/2023, 05:17 PM
Previous filing
Nov 23, 2022
Next filing
Mar 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale -$20K -1.75K -1.13% $11.41 153K Feb 27, 2023 Direct F1, F2, F3
transaction IRWD Class A Common Stock Sale -$20.6K -1.82K -1.19% $11.31 151K Feb 28, 2023 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The reporting person acquired 756 shares of Class A Common Stock under the issuer's employee stock purchase plan on December 31, 2022.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.